Other formats:
BibTeX
LaTeX
RIS
@article{1544703,
author = {Kolčava, Jan and Hulová, Monika and Benešová, Yvonne and Bednařík, Josef and Štourač, Pavel},
article_location = {OXFORD},
article_number = {MAY 2019},
doi = {http://dx.doi.org/10.1016/j.msard.2019.02.019},
keywords = {Multiple sclerosis; Progressive multifocal leukoencephalopathy; Natalizumab; JC virus; Magnetic resonance imaging},
language = {eng},
issn = {2211-0348},
journal = {MULTIPLE SCLEROSIS AND RELATED DISORDERS},
title = {The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings},
url = {http://dx.doi.org/10.1016/j.msard.2019.02.019},
volume = {30},
year = {2019}
}
TY - JOUR
ID - 1544703
AU - Kolčava, Jan - Hulová, Monika - Benešová, Yvonne - Bednařík, Josef - Štourač, Pavel
PY - 2019
TI - The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings
JF - MULTIPLE SCLEROSIS AND RELATED DISORDERS
VL - 30
IS - MAY 2019
SP - 187-191
EP - 187-191
PB - ELSEVIER SCI LTD
SN - 22110348
KW - Multiple sclerosis
KW - Progressive multifocal leukoencephalopathy
KW - Natalizumab
KW - JC virus
KW - Magnetic resonance imaging
UR - http://dx.doi.org/10.1016/j.msard.2019.02.019
L2 - http://dx.doi.org/10.1016/j.msard.2019.02.019
N2 - Background: Natalizumab-related progressive multifocal leukoencephalopathy (PML) is associated with the presence of anti-John Cunningham virus (JCV) antibodies. The aim of this investigation was to evaluate the long-term stability of anti-JCV antibody serum levels and their relation to various demographic, clinical and radiological characteristics in patients suffering from multiple sclerosis (MS). Methods: Seventy-eight relapsing-remitting MS patients treated with natalizumab and evaluated for the presence of serum anti-JCV antibodies over a time period of 1-6 years (3-11 samples) were included in the study. Anti-JCV antibody levels and their changes were correlated with various demographic, clinical and radiological findings. Results: Median follow-up time was 43.5 months, with a median of 5.3 samples available per patient. At baseline, 46 (59%) of the patients were seropositive. During follow-up, anti-JCV antibody status changed from negative to positive or vice versa in 23% of patients. Baseline anti-JCV antibody index correlated positively with age (p = 0.03). Patients: with stable positive anti-JCV antibody index had more T2 hyperintensities (20.2 vs. 13.1; p < 0.007) on cerebral magnetic resonance imaging (MRI) and were also older than the stable negative anti-JCV antibody index group of patients (45.2.vs. 40.3 years; p < 0.01). No significant increase in T2 hyperintensities after seroconversion was revealed. Average duration from beginning of natalizumab therapy to seroconversion fit = 13) was 33 months. Annual seroconversion rate of anti-JCV antibody status was 6.5%. A baseline anti-JCV antibody index of > 0.90 (tt = 33) predicted stable seropositivity (100%), while baseline anti-JCV antibody index <0.20 did not predicted stable seronegativity (59%). PML was not diagnosed in any of the patients studied during the follow-up. Conclusions: A positive baseline anti-JCV antibody index of > 0.90 predicts stable positive JCV serostatus, in contrast with a baseline anti-JCV antibody index of <0.20, which remained negative in 59% of cases. Stable positive anti-JCV index patients have more MRI T2 hyperintensities and are older compared with stable negative anti-JCV index patients.
ER -
KOLČAVA, Jan, Monika HULOVÁ, Yvonne BENEŠOVÁ, Josef BEDNAŘÍK and Pavel ŠTOURAČ. The value of anti-JCV antibody index assessment in multiple sclerosis patients treated with natalizumab with respect to demographic, clinical and radiological findings. \textit{MULTIPLE SCLEROSIS AND RELATED DISORDERS}. OXFORD: ELSEVIER SCI LTD, 2019, vol.~30, MAY 2019, p.~187-191. ISSN~2211-0348. Available from: https://dx.doi.org/10.1016/j.msard.2019.02.019.
|
